Research ExplorerPublicationsDoxorubicin or daunorubicin given upfront in a therapeutic w...

Doxorubicin or daunorubicin given upfront in a therapeutic window are equally effective in children with newly diagnosed acute lymphoblastic leukemia. A randomized comparison in trial CoALL 07-03.

Standard

Doxorubicin or daunorubicin given upfront in a therapeutic window are equally effective in children with newly diagnosed acute lymphoblastic leukemia. A randomized comparison in trial CoALL 07-03. / Escherich, Gabriele; Zimmermann, Martin; Janka-Schaub, Gritta; COALL study group.

In: PEDIATR BLOOD CANCER, Vol. 60, No. 2, 2, 2013, p. 254-257.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Escherich, G, Zimmermann, M, Janka-Schaub, G & COALL study group 2013, 'Doxorubicin or daunorubicin given upfront in a therapeutic window are equally effective in children with newly diagnosed acute lymphoblastic leukemia. A randomized comparison in trial CoALL 07-03.', PEDIATR BLOOD CANCER, vol. 60, no. 2, 2, pp. 254-257. <http://www.ncbi.nlm.nih.gov/pubmed/22948968?dopt=Citation>

APA

Escherich, G., Zimmermann, M., Janka-Schaub, G., & COALL study group (2013). Doxorubicin or daunorubicin given upfront in a therapeutic window are equally effective in children with newly diagnosed acute lymphoblastic leukemia. A randomized comparison in trial CoALL 07-03. PEDIATR BLOOD CANCER, 60(2), 254-257. [2]. http://www.ncbi.nlm.nih.gov/pubmed/22948968?dopt=Citation

Vancouver

Escherich G, Zimmermann M, Janka-Schaub G, COALL study group. Doxorubicin or daunorubicin given upfront in a therapeutic window are equally effective in children with newly diagnosed acute lymphoblastic leukemia. A randomized comparison in trial CoALL 07-03. PEDIATR BLOOD CANCER. 2013;60(2):254-257. 2.

Bibtex

@article{4351c4f3cd6e43328bc22d7c9080bea9,
title = "Doxorubicin or daunorubicin given upfront in a therapeutic window are equally effective in children with newly diagnosed acute lymphoblastic leukemia. A randomized comparison in trial CoALL 07-03.",
abstract = "The anthracyclines daunorubicin (DNR) and doxorubicin (DOX) are among the most important drugs in the treatment of childhood acute lymphoblastic leukemia, however there are conflicting in vitro data about the comparative efficacy and equivalent doses of both anthracyclines. To address the question of in vivo efficacy of both anthracyclines, patients enrolled in the CoALL 07-03 trial were randomized to receive one single dose of either doxorubicin 30?mg/m(2) , daunorubicin 30?mg/m(2) , or daunorubicin 40?mg/m(2) upfront induction therapy.",
keywords = "Humans, Male, Female, Adolescent, Child, Disease-Free Survival, Child, Preschool, Infant, Kaplan-Meier Estimate, Antineoplastic Agents/*therapeutic use, Daunorubicin/*therapeutic use, Doxorubicin/*therapeutic use, Precursor Cell Lymphoblastic Leukemia-Lymphoma/*drug therapy/mortality, Humans, Male, Female, Adolescent, Child, Disease-Free Survival, Child, Preschool, Infant, Kaplan-Meier Estimate, Antineoplastic Agents/*therapeutic use, Daunorubicin/*therapeutic use, Doxorubicin/*therapeutic use, Precursor Cell Lymphoblastic Leukemia-Lymphoma/*drug therapy/mortality",
author = "Gabriele Escherich and Martin Zimmermann and Gritta Janka-Schaub and {COALL study group}",
year = "2013",
language = "English",
volume = "60",
pages = "254--257",
journal = "PEDIATR BLOOD CANCER",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "2",

}

RIS

TY - JOUR

T1 - Doxorubicin or daunorubicin given upfront in a therapeutic window are equally effective in children with newly diagnosed acute lymphoblastic leukemia. A randomized comparison in trial CoALL 07-03.

AU - Escherich, Gabriele

AU - Zimmermann, Martin

AU - Janka-Schaub, Gritta

AU - COALL study group

PY - 2013

Y1 - 2013

N2 - The anthracyclines daunorubicin (DNR) and doxorubicin (DOX) are among the most important drugs in the treatment of childhood acute lymphoblastic leukemia, however there are conflicting in vitro data about the comparative efficacy and equivalent doses of both anthracyclines. To address the question of in vivo efficacy of both anthracyclines, patients enrolled in the CoALL 07-03 trial were randomized to receive one single dose of either doxorubicin 30?mg/m(2) , daunorubicin 30?mg/m(2) , or daunorubicin 40?mg/m(2) upfront induction therapy.

AB - The anthracyclines daunorubicin (DNR) and doxorubicin (DOX) are among the most important drugs in the treatment of childhood acute lymphoblastic leukemia, however there are conflicting in vitro data about the comparative efficacy and equivalent doses of both anthracyclines. To address the question of in vivo efficacy of both anthracyclines, patients enrolled in the CoALL 07-03 trial were randomized to receive one single dose of either doxorubicin 30?mg/m(2) , daunorubicin 30?mg/m(2) , or daunorubicin 40?mg/m(2) upfront induction therapy.

KW - Humans

KW - Male

KW - Female

KW - Adolescent

KW - Child

KW - Disease-Free Survival

KW - Child, Preschool

KW - Infant

KW - Kaplan-Meier Estimate

KW - Antineoplastic Agents/therapeutic use

KW - Daunorubicin/therapeutic use

KW - Doxorubicin/therapeutic use

KW - Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy/mortality

KW - Humans

KW - Male

KW - Female

KW - Adolescent

KW - Child

KW - Disease-Free Survival

KW - Child, Preschool

KW - Infant

KW - Kaplan-Meier Estimate

KW - Antineoplastic Agents/therapeutic use

KW - Daunorubicin/therapeutic use

KW - Doxorubicin/therapeutic use

KW - Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy/mortality

M3 - SCORING: Journal article

VL - 60

SP - 254

EP - 257

JO - PEDIATR BLOOD CANCER

JF - PEDIATR BLOOD CANCER

SN - 1545-5009

IS - 2

M1 - 2

ER -